Home

William Meury

CIK 1536778 · Chief Executive Officer · last filed 2026-07-20

William Meury is a Chief Executive Officer who has filed 55 SEC Form 4 insider transactions across 6 companies since 2011. The most recent filing, for INCY, was dated Jul 20, 2026. Across all open-market trades the lifetime net is −$19.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $28.6M across reported positions. 25 SEC filings were submitted jointly with Actavis plc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$28.57M

Companies

6

Total Filings

55

Lifetime Open-Market Net

-$19.27M

Filer Profile

Reported Address
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022
Related Filers
Actavis plc — 25 joint filings, latest 2020-05-11
INCYTE CORP — 6 joint filings, latest 2026-07-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY Chief Executive Officer 183,129 $126.75 $23.21M $0 5 2026-07-20
SNDX Director 90,000 $20.56 $1.85M -$1.70M 9 2025-02-07
Karuna Therapeutics, Inc. (KRTX) Delisted President and CEO 19,037 $329.83 $6.28M $0 4 2024-03-18
Allergan plc (AGN) Delisted EVP & Chief Commercial Officer 0 — — -$15.29M 18 2020-05-11
ACT See Remarks 71,194 $49.27 $3.51M $0 2 2015-05-19
Forest Laboratories, LLC (FRX) Delisted EVP - Sales and Marketing 87,542 $12.00 $1.05M -$2.28M 11 2013-12-10

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-20 INCY Grant (A) +26,807 $0 EDGAR
2026-07-07 INCY Tax (F) −4,779 -$558.5K EDGAR
2026-04-17 INCY Exer (M) +125,000 $0 EDGAR
2025-07-02 INCY Grant (A) +36,101 $0 EDGAR
2025-06-30 INCY Grant (A) — $0 EDGAR
2025-02-07 SNDX Grant (A) +25,000 $0 EDGAR
2024-03-18 Karuna Therapeutics, Inc. (KRTX) Delisted Disp (D) −29,379 -$9.70M EDGAR
2024-02-15 Karuna Therapeutics, Inc. (KRTX) Delisted Grant (A) — $0 EDGAR
2024-02-09 SNDX Grant (A) +17,000 $0 EDGAR
2023-12-29 Karuna Therapeutics, Inc. (KRTX) Delisted Tax (F) −8,694 -$2.75M EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.